[
    [
        {
            "time": "",
            "original_text": "复星医药：mRNA疫苗国内审批进展正常，首个细胞治疗产品已上市",
            "features": {
                "keywords": [
                    "复星医药",
                    "mRNA疫苗",
                    "国内审批",
                    "进展正常",
                    "细胞治疗",
                    "产品上市"
                ],
                "sentiment_score": 0.75,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物医药",
                    "医疗健康"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "复星医药：mRNA疫苗国内审批进展正常，首个细胞治疗产品已上市",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 6,
                "Time_Proximity": 9,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        }
    ]
]